

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Shewchuk *et al.*

Application No.: 10/543,046

Confirmation No. 7149

Filed: July 21, 2005

Art Unit: 1656

Examiner: David J. Steadman

For: ERBB4 CO-CRYSTAL

Customer No.: 23347

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is submitted in response to the Office Action mailed May 7, 2007. Early examination of the application on the merits is earnestly solicited.

Claims 1-9 are pending in the present application. The Examiner has found lack of unity of invention and has require the election of an invention from the following three groups:

Group I: Claims 1-3 and 9

Group II: Claims 4-6

Group III: Claims 7 and 8


Applicants elect to prosecute the claims of Group II, *i.e.* claims 4-6.
Applicants expressly reserve the right to file divisional applications or take such

other measures deemed necessary to protect the inventions in the remaining claims.

Should the Examiner have any further questions or comments regarding the prosecution of this case, it is respectfully requested that the Examiner telephone the undersigned agent so that further examination of this application may be expedited.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Patent Agent
Registration No. 45,889

Date: June 6, 2007
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
Telephone: (919) 483-1467
Facsimile: (919) 483-7988